<p>药明康德（NASDAQ:PAHC - 获取免费报告）在周五发布的研究报告中被 StockNews.com 的股票研究分析师从 “买入” 评级下调至 “持有” 评级。</p>
<p>获取 <strong>药明康德</strong> 的提醒：</p>
<p>其他一些研究分析师最近也对 PAHC 发表了评论。巴克莱将药明康德的目标价从 20.00 美元上调至 22.00 美元，并在 2 月 10 日的研究报告中给予该股票 “减持” 评级。摩根士丹利将药明康德的目标价从 20.00 美元上调至 25.00 美元，并在 12 月 17 日的报告中给予该公司 “持平” 评级。两位分析师对该股票给予了卖出评级，三位分析师则给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，平均目标价为 21.00 美元。</p>
<p><strong>获取我们最新的药明康德股票分析</strong></p>
<h2>药明康德股票表现</h2>
<p>周五，NASDAQ PAHC 的股票上涨了 0.33 美元，达到 23.64 美元。该股票的交易量为 339,958 股，而其平均交易量为 253,645 股。药明康德的年低为 11.98 美元，年高为 26.55 美元。该公司的债务与股本比率为 2.99，速动比率为 1.37，流动比率为 3.20。该股票的市值为 9.5749 亿美元，市盈率为 49.25，市盈增长比率为 0.45，贝塔值为 0.52。该公司的 50 日移动平均价格为 22.47 美元，200 日移动平均价格为 22.48 美元。</p>
<p>药明康德（NASDAQ:PAHC - 获取免费报告）最近在 2 月 5 日发布了季度财报。该公司报告每股收益为 0.54 美元，超出分析师一致预期的 0.40 美元，超出幅度为 0.14 美元。药明康德的股本回报率为 25.35%，净利润率为 1.75%。研究分析师平均预测药明康德在当前财政年度的每股收益将达到 1.95 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金最近买入和卖出了 PAHC 的股票。Point72 Asia Singapore Pte. Ltd.在第四季度购买了药明康德的新股份，价值约 29,000 美元。Lazard Asset Management LLC 在第四季度将其在药明康德的股份增加了 2,739.7%。Lazard Asset Management LLC 现在拥有 1,647 股该公司的股票，价值 34,000 美元，此前在上个季度又购买了 1,589 股。Quantbot Technologies LP 在第三季度购买了药明康德的新股份，价值约 70,000 美元。Virtus Fund Advisers LLC 在第四季度购买了药明康德的新股份，价值约 69,000 美元。最后，Aquatic Capital Management LLC 在第四季度购买了药明康德的新股份，价值约 69,000 美元。99.34% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于药明康德</h2>
<p>（获取免费报告）</p>
<p>药明康德公司在美国、以色列、巴西、爱尔兰及国际上经营动物健康和矿物营养业务。它通过三个部门运营：动物健康、矿物营养和性能产品。该公司开发、制造和销售各种食品和伴侣动物的产品，包括家禽、猪、肉牛和奶牛、水产养殖和狗。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过药明康德</li>
<li>消费品股票解析</li>
<li>Myers Industries 是否准备好突破？</li>
<li>投资黄金股票的方式和原因</li>
<li>BigBear.ai 的 25% 暴跌是虚惊一场还是抛售？</li>
<li>什么是股息？购买最佳股息股票</li>
<li>博通确认其人工智能前景：股票即将创下新高</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
<p>虽然药明康德目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PAHC

<p>Phibro Animal Health（纳斯达克代码：PAHC）被 StockNews.com 从 “买入” 评级下调至 “持有” 评级。其他分析师的观点不一，巴克莱将其目标价上调至 22 美元，摩根士丹利则上调至 25 美元。该股票目前交易价格为 23.64 美元，市值为 9.5749 亿美元。Phibro 报告每股收益为 0.54 美元，超出预期。机构投资者持有 99.34% 的股份。分析师预测本财年的每股收益为 1.95</p>

<p>Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was downgraded by equities research analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note issued on Friday.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:PAHC - 获取免费报告）在周五发布的研究报告中被 StockNews.com 的股票研究分析师从 “买入” 评级下调至 “持有” 评级。</p>
</div><p>Get <strong>Phibro Animal Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>药明康德</strong> 的提醒：</p>
</div><p>A number of other research analysts also recently commented on PAHC. Barclays upped their price objective on Phibro Animal Health from $20.00 to $22.00 and gave the stock an &#34;underweight&#34; rating in a research note on Monday, February 10th. Morgan Stanley upped their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an &#34;equal weight&#34; rating in a report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Hold&#34; and an average price target of $21.00.</p>
<div class="lb-trans"><p>其他一些研究分析师最近也对 PAHC 发表了评论。巴克莱将药明康德的目标价从 20.00 美元上调至 22.00 美元，并在 2 月 10 日的研究报告中给予该股票 “减持” 评级。摩根士丹利将药明康德的目标价从 20.00 美元上调至 25.00 美元，并在 12 月 17 日的报告中给予该公司 “持平” 评级。两位分析师对该股票给予了卖出评级，三位分析师则给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，平均目标价为 21.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Phibro Animal Health</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的药明康德股票分析</strong></p>
</div><h2>Phibro Animal Health Stock Performance</h2>
<div class="lb-trans"><h2>药明康德股票表现</h2>
</div><p>Shares of NASDAQ PAHC traded up $0.33 during trading on Friday, reaching $23.64. The stock had a trading volume of 339,958 shares, compared to its average volume of 253,645. Phibro Animal Health has a one year low of $11.98 and a one year high of $26.55. The company has a debt-to-equity ratio of 2.99, a quick ratio of 1.37 and a current ratio of 3.20. The stock has a market cap of $957.49 million, a PE ratio of 49.25, a P/E/G ratio of 0.45 and a beta of 0.52. The firm's 50 day moving average price is $22.47 and its two-hundred day moving average price is $22.48.</p>
<div class="lb-trans"><p>周五，NASDAQ PAHC 的股票上涨了 0.33 美元，达到 23.64 美元。该股票的交易量为 339,958 股，而其平均交易量为 253,645 股。药明康德的年低为 11.98 美元，年高为 26.55 美元。该公司的债务与股本比率为 2.99，速动比率为 1.37，流动比率为 3.20。该股票的市值为 9.5749 亿美元，市盈率为 49.25，市盈增长比率为 0.45，贝塔值为 0.52。该公司的 50 日移动平均价格为 22.47 美元，200 日移动平均价格为 22.48 美元。</p>
</div><p>Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. On average, research analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:PAHC - 获取免费报告）最近在 2 月 5 日发布了季度财报。该公司报告每股收益为 0.54 美元，超出分析师一致预期的 0.40 美元，超出幅度为 0.14 美元。药明康德的股本回报率为 25.35%，净利润率为 1.75%。研究分析师平均预测药明康德在当前财政年度的每股收益将达到 1.95 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds have recently bought and sold shares of PAHC. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $29,000. Lazard Asset Management LLC boosted its stake in shares of Phibro Animal Health by 2,739.7% during the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after acquiring an additional 1,589 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $70,000. Virtus Fund Advisers LLC bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $69,000. Finally, Aquatic Capital Management LLC bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $69,000. 99.34% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了 PAHC 的股票。Point72 Asia Singapore Pte. Ltd.在第四季度购买了药明康德的新股份，价值约 29,000 美元。Lazard Asset Management LLC 在第四季度将其在药明康德的股份增加了 2,739.7%。Lazard Asset Management LLC 现在拥有 1,647 股该公司的股票，价值 34,000 美元，此前在上个季度又购买了 1,589 股。Quantbot Technologies LP 在第三季度购买了药明康德的新股份，价值约 70,000 美元。Virtus Fund Advisers LLC 在第四季度购买了药明康德的新股份，价值约 69,000 美元。最后，Aquatic Capital Management LLC 在第四季度购买了药明康德的新股份，价值约 69,000 美元。99.34% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Phibro Animal Health</h2>
<div class="lb-trans"><h2>关于药明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.</p>
<div class="lb-trans"><p>药明康德公司在美国、以色列、巴西、爱尔兰及国际上经营动物健康和矿物营养业务。它通过三个部门运营：动物健康、矿物营养和性能产品。该公司开发、制造和销售各种食品和伴侣动物的产品，包括家禽、猪、肉牛和奶牛、水产养殖和狗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Phibro Animal Health</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Is Myers Industries Poised for a Breakout?</li>
<li>The How and Why of Investing in Gold Stocks</li>
<li>Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过药明康德</li>
<li>消费品股票解析</li>
<li>Myers Industries 是否准备好突破？</li>
<li>投资黄金股票的方式和原因</li>
<li>BigBear.ai 的 25% 暴跌是虚惊一场还是抛售？</li>
<li>什么是股息？购买最佳股息股票</li>
<li>博通确认其人工智能前景：股票即将创下新高</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phibro Animal Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Phibro Animal Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
</div><p>While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Phibro Animal Health (NASDAQ:PAHC) Cut to "Hold" at StockNews.com

药明康德动物健康（NASDAQ:PAHC）在 StockNews.com 被降级为 “持有” 评级